Country: Malta
Language: English
Source: Medicines Authority
EPIRUBICIN HYDROCHLORIDE
Mylan S.A.S. 117 Allee des Parcs, 69800 Saint Priest, France
L01DB03
EPIRUBICIN HYDROCHLORIDE 200 mg
SOLUTION FOR INFUSION OR INJECTION
EPIRUBICIN HYDROCHLORIDE 200 mg
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2013-09-24
Page 1 of 13 PACKAGE LEAFLET: INFORMATION FOR THE USER EPIRUBICIN MYLAN 2 MG/ML SOLUTION FOR INJECTION OR INFUSION Epirubicin hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist IN THIS LEAFLET: 1. What Epirubicin Mylan is and what it is used for? 2. Before you use Epirubicin Mylan. 3. How to use Epirubicin Mylan? 4. Possible side effects. 5. How to store Epirubicin Mylan? 6. Further information. 1. WHAT EPIRUBICIN MYLAN IS AND WHAT IT IS USED FOR? MEDICINAL PRODUCT GROUP Epirubicin belongs to the group of cytostatics (products to fight cancer). Epirubicin makes sure that cancer cells cannot grow any more, which eventually kills them. Epirubicin is administered for the treatment of: - breast cancer; - stomach cancer; - Epirubicin is also used intravesically (directly into the bladder) to treat early (superficial) urinary bladder cancer and help prevent recurrence of bladder cancer after surgery. Epirubicin is often used concomitantly with other cancer fighting medicinal products (in so-called po1ychemotherapy schedules). 2. BEFORE YOU USE EPIRUBICIN MYLAN DO NOT USE EPIRUBICIN MYLAN - if you are ALLERGIC_ _(hypersensitive) to epirubicin, similar medicines (called anthracyclines, see below) or any of the other ingredients of Epirubicin Mylan; - if you have been TREATED BEFO Read the complete document
Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Epirubicin Mylan 2 mg/ml solution for injection or infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: 1 ml of solution for injection or infusion contains 2 mg epirubicin hydrochloride - 1 vial of 25 ml solution contains 50 mg epirubicin hydrochloride. - 1 vial of 100 ml solution contains 200 mg epirubicin hydrochloride Excipient: 1 ml of solution for injection or infusion contains 3.5 mg sodium - 1 vial of 25 ml solution contains 88.5 mg sodium. - 1 vial of 100 ml solution contains 354.1 mg sodium For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection or infusion. A clear red solution, with a pH between 2,5 and 3,5 and osmolality between 240 and 340 mOsmol per kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epirubicin is used in the treatment of a range of neoplastic conditions including; - Breast carcinoma - Gastric carcinoma When administered intravesically, epirubicin has been shown to be beneficial in the treatment of: - Papillary transitional cell carcinoma of the bladder - Carcinoma in-situ of the bladder - Intravesical prophylaxis of recurrence of superficial bladder carcinoma following transurethral resection. For intravesical use a positive benefit-risk ratio could only be established in patients in whom live attenuated BCG is contra-indicated or inappropriate. Epirubicin Mylan 2 mg/ml solution for injection or infusion can be used in polychemotherapy schedules. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Page 2 of 16 Epirubicin is only intended for intravenous or intravesical use. _INTRAVENOUS USE _ It is advisable that the red solution, which should Read the complete document